Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice

Health Economics Review

Table 3 Distribution of comorbidities type among the study population with one comorbidity

	HIV+ patients N = 251	HIV/HCV patients N = 200	Chi-squared
Cardiovascular comorbidities^a	164 [65.59%]	84 [42.00%]	< 0.001
Neurocognitive impairments^b	45 [17.99%]	27 [13.50%]	> 0.050
HBV infection	25 [10.00%]	9 [4.50%]	0.032
Bone events^c	7 [2.80%]	61 [30.51%]	< 0.001
Renal impairments^d	6 [2.41%]	4 [1.99%]	> 0.050
Diabetes	3 [1.20%]	15 [7.50%]	0.001

^aCardiovascular (CDV) events, including hypertension, cardiovascular risk, atrial fibrillation, acute myocardial infarction
^bNeurocognitive impairments, including clinically evident HIV-related dementia, cerebral aneurysm
^cBone events, including osteoporosis, osteopenia, arthritis, bone fractures
^dRenal impairments, including calculosis, proteinuria from grade 2 to 3, and kidney failure

ISSN: 2191-1991